STOCK TITAN
  1. Home
  2. Sec-filings
  3. GILD
  4. [Form 4] GILEAD SCIENCES, INC. Insider Trading Activity

Gilead Sciences (GILD) SVP receives new RSU and stock option grants

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Gilead Sciences SVP receives new equity awards. Senior Vice President of Controllership Erin Burkhart was granted 2,355 restricted stock units and 5,455 non-qualified stock options, each tied to Gilead common stock. Both awards have a four-year vesting schedule, with 25% vesting after one year and the remainder vesting quarterly. Following the grant, Burkhart directly holds 11,245 restricted stock units and 5,455 stock options with a $148.56 exercise price, providing long-term, performance-linked compensation rather than immediate market purchases or sales.

Positive

  • None.

Negative

  • None.
Insider Burkhart Erin
Role SVP, Controllership
Type Security Shares Price Value
Grant/Award Restricted Stock Unit 2,355 $0.00 --
Grant/Award Non-qualified Stock Option (Right to Buy) 5,455 $0.00 --
Holdings After Transaction: Restricted Stock Unit — 11,245 shares (Direct); Non-qualified Stock Option (Right to Buy) — 5,455 shares (Direct)
Footnotes (1)
  1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock. The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested. The stock options have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Burkhart Erin
(Last) (First) (Middle)
333 LAKESIDE DRIVE
(Street)
FOSTER CITY CA 94404
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
GILEAD SCIENCES, INC. [ GILD ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director 10% Owner
X Officer (give title below) Other (specify below)
SVP, Controllership
3. Date of Earliest Transaction (Month/Day/Year)
03/10/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Restricted Stock Unit (1) 03/10/2026 A 2,355 (2) (2) Common Stock 2,355 (1) 11,245 D
Non-qualified Stock Option (Right to Buy) $148.56 03/10/2026 A 5,455 (3) 03/10/2036 Common Stock 5,455 $0 5,455 D
Explanation of Responses:
1. Each restricted stock unit represents the contingent right to receive one share of Gilead Sciences, Inc.'s common stock.
2. The restricted stock units have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
3. The stock options have a 4-year vesting schedule. 25% vest on the first anniversary of the grant date. The balance will vest 6.25% quarterly thereafter until fully vested.
Remarks:
/s/ Amy Kim by Power of Attorney for Erin E. Burkhart 03/12/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider equity awards did Gilead Sciences (GILD) report for Erin Burkhart?

Gilead Sciences reported new equity compensation for SVP Erin Burkhart. She received 2,355 restricted stock units and 5,455 non-qualified stock options, each linked to Gilead common stock, as part of a compensation grant rather than an open-market transaction.

What is the vesting schedule for Erin Burkhart’s new Gilead (GILD) restricted stock units?

The restricted stock units vest over four years. Twenty-five percent vest on the first anniversary of the grant date, and the remaining units vest at 6.25% each quarter thereafter until fully vested, aligning Burkhart’s incentives with longer-term company performance.

How do Erin Burkhart’s new Gilead (GILD) stock options vest and when do they expire?

The stock options also vest over four years and have a long-dated term. Twenty-five percent vest on the first anniversary of the grant date, with the remaining 75% vesting at 6.25% quarterly. The options carry a $148.56 exercise price and expire on March 10, 2036.

Did Gilead SVP Erin Burkhart buy or sell GILD shares in this Form 4 filing?

No open-market buys or sells were reported for Erin Burkhart. The filing shows equity awards: grants of 2,355 restricted stock units and 5,455 non-qualified stock options, both recorded as compensation-related acquisitions rather than discretionary market trading activity.

What are Erin Burkhart’s Gilead (GILD) equity holdings after these awards?

After the awards, Burkhart holds both restricted units and options. She directly holds 11,245 restricted stock units and 5,455 non-qualified stock options, each representing the right to receive Gilead common shares if vested and, for options, exercised at the stated $148.56 exercise price.